Grant of Interim Extension of the Term of U.S. Patent No. 5,610,059; Monovalent Lawsonia Intracellularis Bacterin Vaccine, 10126 [2014-03855]
Download as PDF
<![CDATA[
10126
Federal Register / Vol. 79, No. 36 / Monday, February 24, 2014 / Notices
research scientists, resource managers,
commercial fishermen, recreational
fishermen, outreach experts, and nongovernmental organization
representatives. The Team is tasked
with reviewing and providing
recommendations for the ongoing
research and monitoring, outreach, and
law enforcement components of the
Evaluation Plan.
The SAFMC extended the snapper
grouper bottom fishing restrictions for
the Oculina Experimental Closed Area
(OECA) for an indefinite period in
Snapper Grouper Amendment 13A. The
amendment required that the size and
configuration of the OECA be reviewed
within three years of the
implementation date of 13A and that a
10-year re-evaluation be conducted. The
re-evaluation is the subject of this
webinar.
The items of discussion during the
data webinar are as follows:
1. Participants will initiate
discussions on the re-evaluation of the
OECA.
2. Breakout sessions will be held with
the Evaluation Team to discuss
Research & Monitoring, Outreach, and
Law Enforcement components of the
Evaluation Team.
Although non-emergency issues not
contained in this agenda may come
before this group for discussion, those
issues may not be the subject of formal
action during this meeting. Action will
be restricted to those issues specifically
identified in this notice and any issues
arising after publication of this notice
that require emergency action under
section 305(c) of the Magnuson-Stevens
Fishery Conservation and Management
Act, provided the public has been
notified of the intent to take final action
to address the emergency.
Special Accommodations
This meeting is accessible to people
with disabilities. Requests for auxiliary
aids should be directed to the SAFMC
office (see ADDRESSES) at least 10
business days prior to the meeting.
mstockstill on DSK4VPTVN1PROD with NOTICES
Note: The times and sequence specified in
this agenda are subject to change.
Authority: 16 U.S.C. 1801 et seq.
Dated: February 19, 2014.
Tracey L. Thompson,
Acting Deputy Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. 2014–03816 Filed 2–21–14; 8:45 am]
BILLING CODE 3510–22–P
VerDate Mar<15>2010
17:16 Feb 21, 2014
Jkt 232001
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
[Docket No.: PTO–P–2013–0065]
Grant of Interim Extension of the Term
of U.S. Patent No. 5,610,059;
Monovalent Lawsonia Intracellularis
Bacterin Vaccine
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term
Extension.
AGENCY:
The United States Patent and
Trademark Office has issued an order
granting interim extension under 35
U.S.C. 156(d)(5) for a one-year interim
extension of the term of U.S. Patent No.
5,610,059.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to her attention at
(571) 273–7755; or by email to
Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On December 27, 2013, the Arizona
Board of Regents, on behalf of the
University of Arizona, the patent owner
of record, timely filed an application
under 35 U.S.C. 156(d)(5) for an interim
extension of the term of U.S. Patent No.
5,610,059. The patent claims the
veterinary biological product
monovalent Lawsonia intracellularis
bacterin vaccine. The application
indicates that Intervet, a licensee of the
patent owner, submitted two Product
License Applications (PLA) to the
United States Department of Agriculture
(USDA). In a letter dated April 12, 2011,
USDA acknowledged receipt of the PLA
for a multi-valent vaccine and assigned
the vaccine product code 49L5.RO. In a
letter dated December 22, 2011, USDA
acknowledged receipt of a PLA for a
monovalent vaccine of Lawsonia
intracellularis bacterin and assigned the
vaccine product code 2799.20.
Review of the application indicates
that, except for permission to market or
SUMMARY:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Because the
regulatory review period will continue
beyond the original expiration date of
the patent, March 11, 2014, interim
extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
5,610,059 is granted for a period of one
year from the original expiration date of
the patent.
Dated: February 14, 2014.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination
Policy, United States Patent and Trademark
Office.
[FR Doc. 2014–03855 Filed 2–21–14; 8:45 am]
BILLING CODE 3510–16–P
COMMODITY FUTURES TRADING
COMMISSION
Agency Information Collection
Activities Under OMB Review
Commodity Futures Trading
Commission.
ACTION: Notice.
AGENCY:
In compliance with the
Paperwork Reduction Act, this notice
announces that the Information
Collection Request (ICR) abstracted
below has been forwarded to the Office
of Management and Budget (OMB) for
review and comment. The ICR describes
the nature of the information collection
and its expected costs and burden.
DATES: Comments must be submitted on
or before March 26, 2014.
ADDRESSES: Comments may be
submitted to OMB within 30 days of the
notice’s publication. Comments,
identified by ‘‘Part 41 Relating to
Security Futures Products (OMB Control
No. 3038–0059),’’ should be mailed to
the Office of Information and Regulatory
Affairs, Office of Management and
Budget, Attention: Desk Officer for the
Commodity Futures Trading
Commission, 725 17th Street NW.,
Washington, DC 20503.
Comments may be also be submitted,
regarding the burden estimated or any
other aspect of the information
collection, including suggestions for
reducing the burden, identified by ‘‘Part
41 Relating to Security Futures Products
(OMB Control No. 3038–0059),’’ by any
of the following methods:
• Agency Web site, via its Comments
Online process: https://
SUMMARY:
E:\FR\FM\24FEN1.SGM
24FEN1
]]>Agencies
[Federal Register Volume 79, Number 36 (Monday, February 24, 2014)]
[Notices]
[Page 10126]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-03855]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
[Docket No.: PTO-P-2013-0065]
Grant of Interim Extension of the Term of U.S. Patent No.
5,610,059; Monovalent Lawsonia Intracellularis Bacterin Vaccine
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term Extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting interim extension under 35 U.S.C. 156(d)(5) for a one-
year interim extension of the term of U.S. Patent No. 5,610,059.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On December 27, 2013, the Arizona Board of Regents, on behalf of
the University of Arizona, the patent owner of record, timely filed an
application under 35 U.S.C. 156(d)(5) for an interim extension of the
term of U.S. Patent No. 5,610,059. The patent claims the veterinary
biological product monovalent Lawsonia intracellularis bacterin
vaccine. The application indicates that Intervet, a licensee of the
patent owner, submitted two Product License Applications (PLA) to the
United States Department of Agriculture (USDA). In a letter dated April
12, 2011, USDA acknowledged receipt of the PLA for a multi-valent
vaccine and assigned the vaccine product code 49L5.RO. In a letter
dated December 22, 2011, USDA acknowledged receipt of a PLA for a
monovalent vaccine of Lawsonia intracellularis bacterin and assigned
the vaccine product code 2799.20.
Review of the application indicates that, except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for one year as required by 35
U.S.C. 156(d)(5)(B). Because the regulatory review period will continue
beyond the original expiration date of the patent, March 11, 2014,
interim extension of the patent term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 5,610,059 is granted for a period of one year from the
original expiration date of the patent.
Dated: February 14, 2014.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination Policy, United States Patent
and Trademark Office.
[FR Doc. 2014-03855 Filed 2-21-14; 8:45 am]
BILLING CODE 3510-16-P
